[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352735-105":59,"doc-detail-352735-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","real-world-outcomes-with-chemotherapy-and-immunotherapy-in-metastatic-poorly-differentiated-gastroenteropancreatic-neuroendocrine-carcinomas-research-article","Real World Outcomes With Chemotherapy and Immunotherapy in Metastatic Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas - Research Article","","Gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (GEP-NECs) are aggressive cancers in which cytotoxic chemotherapy serves as the core treatment. Immunotherapy with immune checkpoint inhibitors alongside chemotherapy is recommended for lung NECs, but evidence for GEP-NECs remains limited. Using the National Cancer Database, the study analyzes systemic-therapy outcomes for metastatic GEP-NEC cases diagnosed between 2018 and 2022, assessing overall survival with Kaplan–Meier and Cox modeling.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-outcomes-with-chemotherapy-and-immunotherapy-in-metastatic-poorly-differentiated-gastroenteropancreatic-neuroendocrine-carcinomas-research-article/352735/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-outcomes-with-chemotherapy-and-immunotherapy-in-metastatic-poorly-differentiated-gastroenteropancreatic-neuroendocrine-carcinomas-research-article/352735.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why is chemotherapy the backbone for metastatic GEP-NECs?","Question",{"text":112,"@type":113},"Gastroenteropancreatic poorly differentiated neuroendocrine carcinomas are aggressive, and cytotoxic chemotherapy is described as the backbone of treatment in the study background.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was overall survival analyzed in this study?",{"text":117,"@type":113},"Cases of metastatic GEP-NECs (diagnosis years 2018–2022) were identified in the National Cancer Database, and overall survival was evaluated using Kaplan–Meier estimates and Cox proportional hazards regression.",{"name":119,"@type":110,"acceptedAnswer":120},"What was the study’s main finding about combining chemoIO versus chemotherapy alone?",{"text":121,"@type":113},"Patients treated with chemoIO had prolonged overall survival compared with chemotherapy alone, with median OS of 10.51 months versus 8.31 months and a hazard ratio of 0.77 (p \u003C 0.001).",{"name":123,"@type":110,"acceptedAnswer":124},"Did the study observe benefits across different histological subgroups?",{"text":125,"@type":113},"Yes. The association between chemoIO treatment and improved survival was significant across histological subgroups, including small-cell, large-cell, and other/not specified categories.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},352735,1790129686,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nReal World Outcomes With Chemotherapy and Immunotherapy in Metastatic Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas  \nRushabh Gujarathi1  | Samantha Kwock2 | Faith Abodunrin3 | Namrata Setia4 | Xavier M. Keutgen5  | Chih-Yi Liao3  \n1Department of Medicine, University of Louisville, Louisville, Kentucky, USA | 2University of Chicago Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA | 3Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA | 4Department of Pathology, University of Chicago, Chicago, Illinois, USA | 5Section of Endocrine Surgery, Department of Surgery, University of Chicago, Chicago, Illinois, USA  \nCorrespondence: Chih-Yi Liao ([andyliao@uchicagomedicine.org](andyliao@uchicagomedicine.org))  \nReceived: 21 October 2025 | Revised: 30 January 2026 | Accepted: 31 March 2026  \nKeywords: chemotherapy | immunotherapy | ncdb | neuroendocrine carcinomas | neuroendocrine tumors  \nABSTRACT  \nBackground: Gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (GEP-NECs) are aggressive cancers where cytotoxic chemotherapy is the backbone of treatment. While the addition of immunotherapy with immune checkpoint inhibitors (IOs) to chemotherapy is recommended for lung NECs, evidence regarding IO efficacy in GEP-NECs is limited. We explore outcomes with systemic therapies in patients with metastatic GEP-NECs using the National Cancer Database (NCDB) . Methods: Cases of metastatic GEP-NECs with years of diagnosis between 2018 and 2022 were identified within the NCDB. Overall survival (OS) was analyzed using Kaplan–Meier estimations and Cox proportional hazards regression.  \nResults: Four thousand one hundred twenty-seven cases were included. 1209 (29.29%) patients did not receive any systemic therapy (chemotherapy/immunotherapy/both) . Among the 2918 patients that received systemic therapy, 758 (25.98%) patients received immunotherapy (immunotherapy alone = 21; chemotherapy plus immunotherapy [chemoIO] = 737) . The percentage of patients receiving immunotherapy alongside chemotherapy increased from 12.27% in 2018 to 34.18% in 2022. Two thousand two hundred eighty cases were included for survival analysis. Patients treated with chemoIO (N = 532) had prolonged OS versus chemotherapy alone (N = 1748), with median OS of 10.51 months vs. 8.31 months (HR, 0.77; 95% CI, 0.69–0.85; p \u003C 0.001) . The association was significant in all histological subgroups (small-cell, p \u003C 0.001; large-cell, p = 0.04; others/not specified, p = 0.01) . Conclusions: Combination chemoIO may improve survival in metastatic GEP-NECs as compared to chemotherapy alone. Results of currently ongoing clinical trials exploring the role of immunotherapy in extrapulmonary NECs may help guide clinical practice in GEP-NECs.  \n1 | Introduction  \nNeuroendocrine Neoplasms (NENs) are tumors that express biomarkers associated with the cellular pathways of neuroendocrine cells [1]. Although rare, these tumors have seen a notable increase in incidence over recent decades [2, 3] . NENs can broadly be categorized into well-differentiated neuroendocrine  \ntumors (NETs) and poorly differentiated neuroendocrine carcinomas (PD-NECs or NECs) based on histological retention of neuroendocrine morphological and molecular features [4, 5] . The 2022 WHO classification of neuroendocrine neoplasms defines NECs based on poorly differentiated neuroendocrine morphology, characterized by solid sheet or nodular growth patterns with frequent geographic necrosis, and recognizes  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.  \nC","cbCaidXRfnkRPkst","https://ap.wps.com/l/cbCaidXRfnkRPkst","pdf",802497,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"Why is chemotherapy the backbone for metastatic GEP-NECs?\",\"answer\":\"Gastroenteropancreatic poorly differentiated neuroendocrine carcinomas are aggressive, and cytotoxic chemotherapy is described as the backbone of treatment in the study background.\"},{\"question\":\"How was overall survival analyzed in this study?\",\"answer\":\"Cases of metastatic GEP-NECs (diagnosis years 2018–2022) were identified in the National Cancer Database, and overall survival was evaluated using Kaplan–Meier estimates and Cox proportional hazards regression.\"},{\"question\":\"What was the study’s main finding about combining chemoIO versus chemotherapy alone?\",\"answer\":\"Patients treated with chemoIO had prolonged overall survival compared with chemotherapy alone, with median OS of 10.51 months versus 8.31 months and a hazard ratio of 0.77 (p \\u003c 0.001).\"},{\"question\":\"Did the study observe benefits across different histological subgroups?\",\"answer\":\"Yes. The association between chemoIO treatment and improved survival was significant across histological subgroups, including small-cell, large-cell, and other/not specified categories.\"}]","Real World Outcomes With Chemotherapy and Immunotherapy in Metastatic Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas - Research Article | PDF",1790101155,28,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7887919401c543fe285fa1da39206dcf.webp",983,1291,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8e5d565fcd95b759b1ef02da7dcf8d8.webp",982,1290,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/452717a0ebb7bbf81aa5a83bfa7c098e.webp",981,1289,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5a331e11d0315c6b13c27bfe0a3dc77.webp",980,1287]